Gemcitabine therapy in patients with advanced pancreatic cancer.
| Autor: | Min YJ; Department of Internal Medicine, Ulsan University Hospital, University of Ulsan College of Medicine, 290-3 Cheonha-dong, Dong-gu, Ulsan, 682-060, Korea. yjmin@uuh.ulsan.kr, Joo KR, Park NH, Yun TK, Nah YW, Nam CW, Park JH |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | The Korean journal of internal medicine [Korean J Intern Med] 2002 Dec; Vol. 17 (4), pp. 259-62. |
| DOI: | 10.3904/kjim.2002.17.4.259 |
| Abstrakt: | Background: Advanced, unresectable pancreatic cancer is an extremely aggressive disease. The 5-year survival rate for pancreatic cancer is only less than 5%. Current therapeutic options for patients with locally advanced or metastatic disease are limited. This analysis is a retrospective evaluation of the efficacy and toxicity of gemcitabine regimen as first-line chemotherapy in patients with advanced pancreatic cancer. Methods: Seventeen chemotherapy-naive patients with advanced or recurred pancreatic cancer were consecutively treated. Gemcitabine was diluted in normal saline and administered intravenously over 1 hour. Gemcitabine 1,000 mg/m2 was administered once weekly for 3 out of every 4 weeks. Results: The median age of patients was 55 years (range 44-82 years). Based on RECIST criteria, there were 5 cases of stable disease (45%) and 6 cases of progressive disease (55%) among the 11 assessable patients. The median survival time was 189 days (range, 84 to 409 days), the 1 year survival rate was 18% in all 17 patients. Grade 3-4 toxic side effect was leucopenia only (29%) and was easily managed without infection. Conclusion: Gemcitabine is well tolerated, but has no objective response in advanced pancreatic cancer. |
| Databáze: | MEDLINE |
| Externí odkaz: |
|